- Home
- VII vs IFRX Comparison
VII vs IFRX Comparison
Compare VII & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VII | IFRX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 308.1M | 303.4M |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VII | IFRX |
|---|---|---|
| Price | $9.85 | $2.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 8.8K | ★ 891.4K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.81 | $0.80 |
| 52 Week High | $9.85 | $2.95 |
Technical Indicators
Market Signals| Indicator | VII | IFRX |
|---|---|---|
| Relative Strength Index (RSI) | 47.71 | 59.31 |
| Support Level | $9.81 | $1.58 |
| Resistance Level | N/A | $2.94 |
| Average True Range (ATR) | 0.01 | 0.12 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 87.50 | 86.21 |
Price Performance
Historical ComparisonAbout VII Viking Acquisition Corp. II Class A Ordinary Shares
Viking Acquisition Corp II is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About IFRX InflaRx N.V.
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.